Epalrestat is a

Epalrestat is analdose reductase inhibitor. There by it reduces the formation of sorbitol from glucose. Sorbitol acts like a tissue toxin. "Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, paicularly in subjects with good glycemic control and limited microangiopathy." Epalrestat is a drug that we use in diabetic but it is not a antidiabetic drug (i.e. it does not reduce the blood sugar level).